Respiratory response to toluene diisocyanate depends on prior frequency and concentration of dermal sensitization in mice.
Occupational asthma is the principal cause of work-related respiratory disease in the industrial world. In the absence of satisfactory models for predicting the potential of low molecular weight chemicals to cause asthma, we verified that dermal sensitization prior to intranasal challenge influences the respiratory response using toluene diisocyanate (TDI), a known respiratory sensitizer. BALB/c mice received TDI or vehicle (acetone/olive oil) on each ear on three consecutive days (days 1, 2, and 3; 0.3 or 3% TDI) or only once (day 1, 1% TDI). On day 7, the mice received similar dermal applications of vehicle or the same concentration of TDI as before ("boost"). On day 10, they received an intranasal dose of TDI (0.1%) or vehicle. Ventilatory function was monitored by whole body plethysmography for 40 min after intranasal application, and reactivity to inhaled methacholine was assessed 24 h later. Pulmonary inflammation was assessed by bronchoalveolar lavage and histology. Mice that received an intranasal dose of TDI without having received a prior dermal application of TDI did not exhibit any ventilatory response or inflammatory changes compared to vehicle controls. In contrast, mice that had received prior application(s) of TDI, even if only on day 7, exhibited the following: ventilatory responses, compatible with bronchoconstriction, immediately after intranasal application with TDI; enhanced methacholine responsiveness 24 h later; and pulmonary inflammation characterized by neutrophils. This was, however, not the case in mice that received the highest dermal amount of TDI (3% on days 1, 2, and 3). These findings suggest that respiratory response to TDI depends on prior frequency and concentration of dermal sensitization in mice.
Vanoirbeek
Jeroen A J
JA
Laboratories of Pneumology (Lung Toxicology), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
Tarkowski
Maciej
M
Ceuppens
Jan L
JL
Verbeken
Erik K
EK
Nemery
Benoit
B
Hoet
Peter H M
PH
D000281:Administration, Intranasal; D000818:Animals; D001249:Asthma / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016085:Bronchoconstrictor Agents / Q000494:pharmacology; D017449:Dermatitis, Allergic Contact / Q000473:pathology / Q000503:physiopathology*; D004195:Disease Models, Animal; D007073:Immunoglobulin E / Q000096:biosynthesis; D008297:Male; D016210:Methacholine Chloride / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D016273:Occupational Exposure; D010993:Plethysmography, Whole Body; D015656:Respiratory Mechanics / Q000187:drug effects*; D014051:Toluene 2,4-Diisocyanate / Q000008:administration & dosage / Q000633:toxicity*
D016085:Bronchoconstrictor Agents; D016210:Methacholine Chloride; D014051:Toluene 2,4-Diisocyanate; D007073:Immunoglobulin E